Zytux, Rituximab Biosimilar, May Be Safe, Effective for Hard-to-treat MG

Zytux, Rituximab Biosimilar, May Be Safe, Effective for Hard-to-treat MG

307044

Zytux, Rituximab Biosimilar, May Be Safe, Effective for Hard-to-treat MG

Zytux, a biosimilar of rituximab, may be effective and safe for patients with hard-to-treat myasthenia gravis (MG), a small study suggests. In the study, adding Zytux to prednisolone — a corticosteroid — eased MG symptoms, and improved patients’ quality of life, as well as their ability to carry out daily tasks. These findings were reported in “Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar,”…

You must be logged in to read/download the full post.